Discounted Cash Flow (DCF) Analysis Levered

BioNano Genomics, Inc. WT EXP 08212... (BNGOW)

$0.05

+0.01 (+19.90%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue 1210.138.5017.9827.8037.1549.6366.3188.60118.37
Revenue (%)
Operating Cash Flow -19.94-29.53-38.31-71.93-124.82-130.55-174.43-233.05-311.38-416.03
Operating Cash Flow (%)
Capital Expenditure -0.33-0.06-0.14-0.30-0.47-0.63-0.84-1.12-1.49-1.99
Capital Expenditure (%)
Free Cash Flow -20.28-29.59-38.46-72.23-125.28-131.18-175.26-234.17-312.87-418.02

Weighted Average Cost Of Capital

Share price $ 0.05
Beta 0.000
Diluted Shares Outstanding -
Cost of Debt
Tax Rate -1.44
After-tax Cost of Debt 2.55%
Risk-Free Rate
Market Risk Premium
Cost of Equity 3.608
Total Debt 11.67
Total Equity -
Total Capital -
Debt Weighting -
Equity Weighting -
Wacc

Build Up Free Cash Flow

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue 1210.138.5017.9827.8037.1549.6366.3188.60118.37
Operating Cash Flow -19.94-29.53-38.31-71.93-124.82-130.55-174.43-233.05-311.38-416.03
Capital Expenditure -0.33-0.06-0.14-0.30-0.47-0.63-0.84-1.12-1.49-1.99
Free Cash Flow -20.28-29.59-38.46-72.23-125.28-131.18-175.26-234.17-312.87-418.02
WACC
PV LFCF -----
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) -426.38
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt 6.58
Equity Value -
Shares Outstanding -
Equity Value Per Share -